Advertisement
Singapore markets closed

  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     

  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     

  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • Bitcoin USD

    61,605.43
    +700.14 (+1.15%)
     

  • CMC Crypto 200

    1,277.49
    -6.34 (-0.49%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • Dow

    39,118.86
    -45.20 (-0.12%)
     

  • Nasdaq

    17,732.60
    -126.08 (-0.71%)
     

  • Gold

    2,336.90
    +0.30 (+0.01%)
     

  • Crude Oil

    81.46
    -0.28 (-0.34%)
     

  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     

  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     

  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     

  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Zacks Equity Research
·3-min read

Sorrento Therapeutics SRNE moved up 6.21% in August, during market hours, after the drugmaker announced positive results from its drug candidate, Abivertinib. The drug is being evaluated for treating advanced non-small cell lung cancer (NSCLC) patients resistant to first-line EGFR kinase inhibitor therapies.

Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor being evaluated by Sorrento in a pivotal late-stage study in China.

The company reported an overall response rate (ORR) of 56.5% (118/209) in 209 evaluable NSCLC patients being treated with abivertinib. The candidate also exhibited a complete response rate (CRR) of 5.3% (11/209) and median overall survival (OS) of 28.2 months in the aforementioned patient population.

Sorrento is ending the study of abivertinib, and based on this data, it will be preparing to apply for a pre-new drug application (NDA) meeting with the FDA. The company also intends to submit documentation for the approval of abivertinib as a treatment for NSCLC to regulatory agencies of other countries as well.

ADVERTISEMENT

Sorrento shares have declined 57% in the year-to-date period compared with the industry’s decline of 21.6%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The targeted market represents a significant market opportunity.

Sorrento is a clinical and commercial stage biopharma company focused on developing next generation treatments for infectious diseases, pain and cancer. The company added abivertinib to its portfolio, as a part of its ACEA Therapeutics acquisition, completed in June 2021. The acquisition significantly strengthened Sorrento’s oncology franchise.

Sorrentto also received an investigational new drug (“IND”) application clearance from the FDA, in May 2022, for evaluating abivertinib in patients with metastatic castrate-resistant prostate cancer (mCRPC) in the United States in a phase II MAVERICK study.

In March 2022, the company received FDA clearance for the commencement of phase II/III study for abivertinib in the treatment of hospitalized patients with severe pneumonia due to COVID-19. The late-stage study will be conducted at multiple sites in the United States, Brazil and Mexico.

Sorrento’s abivertinib for treating NSCLC, if and when approved, will face stiff competition from AstraZeneca’s AZN already approved lung-cancer drug Tagrisso (Osimertinib).

AZN’s Tagrisso has already been approved in the United States, European Union, Japan and China as a second-line treatment option for patients with EGFR mutation-positive NSCLC.

Sorrento Therapeutics, Inc. Price

 

Sorrento Therapeutics, Inc. price | Sorrento Therapeutics, Inc. Quote

 

Zacks Rank and Stocks to Consider

Currently, SRNE has a Zacks Rank #3 (Hold).

Some better stocks in the same sector are Inozyme Pharma INZY and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Inozyme’s loss per share estimates for 2022 have narrowed from $2.08 to $1.84 in the past 30 days. The same for 2023 has narrowed from $1.95 to $1.82 in the same time frame.

Earnings of Inozyme missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average earnings surprise for INZY is 6.65%.

Pliant’s loss per share estimates for 2022 have improved from $3.28 to $3.01 in the past 30 days. The same for 2023 has narrowed from $3.68 to $3.29 in the same time frame.

Earnings of Pliant beat estimates in two of the trailing four quarters, were in line in one and missed the same on the remaining occasion. The average earnings surprise for PLRX is 0.90%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Sorrento Therapeutics, Inc. (SRNE) : Free Stock Analysis Report
 
Pliant Therapeutics, Inc. (PLRX) : Free Stock Analysis Report
 
Inozyme Pharma, Inc. (INZY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research